L Longobardi1, J M Jordan2, X A Shi3, J B Renner4, T A Schwartz5, A E Nelson6, D A Barrow7, V B Kraus8, A Spagnoli9. 1. Division of Rheumatology, Allergy and Immunology and the Thurston Arthritis Research Center, University of North Carolina-Chapel Hill, NC, USA. Electronic address: lara_longobardi@med.unc.edu. 2. Division of Rheumatology, Allergy and Immunology and the Thurston Arthritis Research Center, University of North Carolina-Chapel Hill, NC, USA. Electronic address: joanne_jordan@med.unc.edu. 3. Division of Rheumatology, Allergy and Immunology and the Thurston Arthritis Research Center, University of North Carolina-Chapel Hill, NC, USA. Electronic address: xyshi@email.unc.edu. 4. Department of Radiology, University of North Carolina-Chapel Hill, NC, USA. Electronic address: jordan_renner@med.unc.edu. 5. Division of Rheumatology, Allergy and Immunology and the Thurston Arthritis Research Center, University of North Carolina-Chapel Hill, NC, USA; Department of Biostatistics, Gillings School of Global Public Health, University of North Carolina-Chapel Hill, NC, USA. Electronic address: tschwart@email.unc.edu. 6. Division of Rheumatology, Allergy and Immunology and the Thurston Arthritis Research Center, University of North Carolina-Chapel Hill, NC, USA. Electronic address: amanda_nelson@med.unc.edu. 7. School of Dentistry, University of North Carolina-Chapel Hill, NC, USA. Electronic address: David_Barrow@unc.edu. 8. Duke Molecular Physiology Institute and Division of Rheumatology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA. Electronic address: vbk@duke.edu. 9. Department of Pediatrics, Rush University Medical Center, Chicago, IL, USA. Electronic address: Anna_Spagnoli@rush.edu.
Abstract
OBJECTIVE: Our study analyzes the association between chemokine-ligand-2 (CCL2) serum concentrations at baseline and knee radiographic osteoarthritis (OA) (knee-rOA), knee-rOA progression, individual radiographic features and knee symptomatic OA at 5-year follow-up. DESIGN: OA outcomes were analyzed in a community-based cohort including a baseline enrollment and a 5-year follow-up. Baseline CCL2 serum concentrations were assessed by multiplex assay and associated with presence or progression of individual radiographic features at 5-year follow-up. Separate multiple logistic regression models were used to examine adjusted associations between baseline CCL2 and each of the knee OA variables at follow-up. CCL2 at baseline was modeled as an explanatory variable, whereas each of the knee OA variables at follow-up served as the response variables. Models were adjusted for age, BMI, race, and sex. Trend tests were conducted to assess any linear effect on outcomes across CCL2 tertiles. RESULTS: Participants (n = 168) had a median age of 57-years and median BMI of 29 kg/m2. About 63% of all participants were women, and 58% Caucasian (42% African American). In adjusted logistic models, continuous log-CCL2 was significantly associated with knee-rOA. For each unit increase in log CCL2, the odds of having knee-rOA at follow-up was increased by 72%. CCL2 tertiles showed significant linear associations with presence and progression of knee-rOA and medial joint space narrowing (JSN), but not with presence or progression of osteophytes, bone sclerosis, knee symptoms, or symptomatic knee-rOA. CONCLUSIONS: Serum CCL2 may help to elucidate some mechanisms of joint destruction and identify individuals with higher odds of structural knee changes.
OBJECTIVE: Our study analyzes the association between chemokine-ligand-2 (CCL2) serum concentrations at baseline and knee radiographic osteoarthritis (OA) (knee-rOA), knee-rOA progression, individual radiographic features and knee symptomatic OA at 5-year follow-up. DESIGN: OA outcomes were analyzed in a community-based cohort including a baseline enrollment and a 5-year follow-up. Baseline CCL2 serum concentrations were assessed by multiplex assay and associated with presence or progression of individual radiographic features at 5-year follow-up. Separate multiple logistic regression models were used to examine adjusted associations between baseline CCL2 and each of the knee OA variables at follow-up. CCL2 at baseline was modeled as an explanatory variable, whereas each of the knee OA variables at follow-up served as the response variables. Models were adjusted for age, BMI, race, and sex. Trend tests were conducted to assess any linear effect on outcomes across CCL2 tertiles. RESULTS:Participants (n = 168) had a median age of 57-years and median BMI of 29 kg/m2. About 63% of all participants were women, and 58% Caucasian (42% African American). In adjusted logistic models, continuous log-CCL2 was significantly associated with knee-rOA. For each unit increase in log CCL2, the odds of having knee-rOA at follow-up was increased by 72%. CCL2 tertiles showed significant linear associations with presence and progression of knee-rOA and medial joint space narrowing (JSN), but not with presence or progression of osteophytes, bone sclerosis, knee symptoms, or symptomatic knee-rOA. CONCLUSIONS: Serum CCL2 may help to elucidate some mechanisms of joint destruction and identify individuals with higher odds of structural knee changes.
Authors: Joanne M Jordan; Charles G Helmick; Jordan B Renner; Gheorghe Luta; Anca D Dragomir; Janice Woodard; Fang Fang; Todd A Schwartz; Lauren M Abbate; Leigh F Callahan; William D Kalsbeek; Marc C Hochberg Journal: J Rheumatol Date: 2007-01 Impact factor: 4.666
Authors: L Longobardi; J D Temple; L Tagliafierro; H Willcockson; A Esposito; N D'Onofrio; E Stein; T Li; T J Myers; H Ozkan; M L Balestrieri; V Ulici; R F Loeser; A Spagnoli Journal: Osteoarthritis Cartilage Date: 2016-11-14 Impact factor: 6.576
Authors: Harini Raghu; Christin M Lepus; Qian Wang; Heidi H Wong; Nithya Lingampalli; Francesca Oliviero; Leonardo Punzi; Nicholas J Giori; Stuart B Goodman; Constance R Chu; Jeremy B Sokolove; William H Robinson Journal: Ann Rheum Dis Date: 2016-12-13 Impact factor: 19.103
Authors: Huseyin Ozkan; Martina Di Francesco; Helen Willcockson; José Valdés-Fernández; Valentina Di Francesco; Froilán Granero-Moltó; Felipe Prósper; Paolo Decuzzi; Lara Longobardi Journal: Drug Deliv Transl Res Date: 2022-09-15 Impact factor: 5.671